These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 2785254)

  • 1. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
    Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC; Hsiao MH; Pattengale PK
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission.
    Dabholkar M; Advani S; Tatake R; Gangal S
    Leuk Res; 1986; 10(2):203-9. PubMed ID: 3456474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on natural killer cells in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake RJ; Advani S; Gangal SG
    Neoplasma; 1990; 37(1):47-53. PubMed ID: 1690865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory effect of cytokines on natural killer and antibody dependent cellular cytotoxicity directed to squamous cell carcinoma targets by lymphocytes from oral cancer patients.
    Desai SA; Maniar HS; Rao RS; Fakih AR; Gangal SG
    Eur J Cancer B Oral Oncol; 1993 Jan; 29B(1):69-73. PubMed ID: 8180580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
    Chang WC; Fujimiya Y; Casteel N; Pattengale P
    Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies.
    Tatake RJ; Maniar HS; Chiplunkar SV; Somasundaram R; Amin MK; Saikia T; Gangal SG
    J Clin Lab Immunol; 1990 Feb; 31(2):87-91. PubMed ID: 1966990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.
    Tomescu C; Tebas P; Montaner LJ
    AIDS; 2017 Mar; 31(5):613-622. PubMed ID: 28225449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
    Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
    Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of human natural killer cell activity by recombinant human interleukin 2.
    Shaw AR; Bleackley RC; Merryweather JP; Barr PJ
    Cell Immunol; 1985 Feb; 90(2):547-54. PubMed ID: 3881192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
    Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
    Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of natural killer cells in the treatment of chronic myeloid leukemia.
    Silla LM; Whiteside TL; Ball ED
    J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
    Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
    Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
    Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
    Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of natural killer cytotoxicity by Escherichia coli-derived human interferon gamma.
    Platsoucas CD
    Scand J Immunol; 1986 Jul; 24(1):93-108. PubMed ID: 3088722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological effects of interferon-alpha on chronic myelogenous leukemia.
    de Castro FA; Palma PV; Morais FR; Simões BP; Carvalho PV; Ismael SJ; Lima CP; Voltarelli JC
    Leuk Lymphoma; 2003 Dec; 44(12):2061-7. PubMed ID: 14959848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.